Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02565108
Recruitment Status : Completed
First Posted : October 1, 2015
Results First Posted : August 23, 2018
Last Update Posted : August 23, 2018
Sponsor:
Information provided by (Responsible Party):
GW Research Ltd

Tracking Information
First Submitted Date  ICMJE September 29, 2015
First Posted Date  ICMJE October 1, 2015
Results First Submitted Date  ICMJE June 25, 2018
Results First Posted Date  ICMJE August 23, 2018
Last Update Posted Date August 23, 2018
Actual Study Start Date  ICMJE January 20, 2016
Actual Primary Completion Date July 21, 2016   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 26, 2018)
  • Pharmacokinetics (PK): Maximum Measured Plasma Concentration (Cmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33 [ Time Frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33 ]
    The Cmax of CLB and its primary metabolite N-desmethylclobazam (N-CLB) was measured on Day 1 (before beginning GWP42003-P treatment; participants were taking CLB only) and Day 33 (following 21 days of GWP42003-P or placebo maintenance; participants were taking CLB and GWP42003-P or CLB and placebo). PK samples were taken at time points relative to the morning dose of CLB, as follows: Predose, 15 minutes (min), 30 min, 1 hour (h), 1.5 h, 2 h, 4 h, 6 h, 12 h, and 24 h. One participant in the placebo group was excluded from the PK set because placebo was administered on Day 1, after predose sampling. Six participants in the GWP42003-P group were excluded from the PK set because of GWP42003-P and/or CLB dose modification, discontinuation of IMP, discontinuation from trial, or administration of incorrect IMP dose.
  • PK: Time To The Maximum Plasma Concentration (Tmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33 [ Time Frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33 ]
    The tmax of CLB and its primary metabolite N-CLB was measured on Day 1 (before beginning GWP42003-P treatment; participants were taking CLB only) and Day 33 (following 21 days of GWP42003-P or placebo maintenance; participants were taking CLB and GWP42003-P or CLB and placebo). PK samples were taken at time points relative to the morning dose of CLB, as follows: Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 12 h, and 24 h. One participant in the placebo group was excluded from the PK set because placebo was administered on Day 1, after predose sampling. Six participants in the GWP42003-P group were excluded from the PK set because of GWP42003-P and/or CLB dose modification, discontinuation of IMP, discontinuation from trial, or administration of incorrect IMP dose.
  • PK: Area Under The Plasma Concentration‑Time Curve Over A Dosing Interval, Where Tau Is The Dosing Interval (AUCtau) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33 [ Time Frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33 ]
    The AUCtau of CLB and its primary metabolite N-CLB was measured on Day 1 (before first GWP42003-P dose; participants were taking CLB only) and Day 33 (following 21 days of GWP42003-P or placebo maintenance; participants were taking CLB and GWP42003-P or CLB and placebo). PK samples were taken at time points relative to the morning dose of CLB, as follows: Predose, 15 min, 30 min, 1 h, 1.5 h, 2 h, 4 h, 6 h, 12 h, and 24 h. One participant in the placebo group was excluded from the PK set because placebo was administered on Day 1, after predose sampling. Six participants in the GWP42003-P group were excluded from the PK set because of GWP42003-P and/or CLB dose modification, discontinuation of IMP, discontinuation from trial, or administration of incorrect IMP dose.
  • PK: Geometric Mean Ratios Of CLB And N-CLB For Cmax On Day 33 Compared With Day 1 [ Time Frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33 ]
    The Day 33 compared to Day 1 geometric mean ratios of CLB and N-CLB were calculated for Cmax to look for evidence of drug-drug interactions between GWP42003-P/Placebo and CLB and between GWP42003-P/Placebo and N-CLB. A standard 90% confidence interval (CI) approach for the between time point ratios of geometric means of Cmax was carried out on a logarithmic scale using a linear mixed effect model. The no-effect boundary was set between 0.5 and 2.0, and if the 90% CI for the ratio of the geometric means of a PK variable fell within the interval [0.5, 2.0], a lack of meaningful effect was declared. Estimates were back transformed to provide summaries on the original scale. The model included a fixed effect term for PK assessment period. An unstructured covariance matrix was used. Kenward and Roger's method was used to calculate the denominator degrees of freedom for the fixed effects.
  • PK: Geometric Mean Ratios Of CLB And N-CLB For AUCtau On Day 33 Compared With Day 1 [ Time Frame: Predose, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 h postdose on Days 1 and 33 ]
    The Day 33 compared to Day 1 geometric mean ratios of CLB and N-CLB were calculated for AUCtau to look for evidence of drug-drug interactions between GWP42003-P/Placebo and CLB and between GWP42003-P/Placebo and N-CLB. A standard 90% CI approach for the between time point ratios of geometric means of AUCtau was carried out on a logarithmic scale using a linear mixed effect model. The no-effect boundary was set between 0.5 and 2.0, and if the 90% CI for the ratio of the geometric means of a PK variable fell within the interval [0.5, 2.0], a lack of meaningful effect was declared. Estimates were back transformed to provide summaries on the original scale. The model included a fixed effect term for PK assessment period. An unstructured covariance matrix was used. Kenward and Roger's method was used to calculate the denominator degrees of freedom for the fixed effects.
Original Primary Outcome Measures  ICMJE
 (submitted: September 29, 2015)
  • Maximum plasma concentration (Cmax) of CLB, N-CLB, CBD and CBD major metabolites. [ Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose. ]
    The Cmax of CLB, N-CLB, cannabidiol (CBD) and CBD major metabolites are presented.
  • Time to the maximum plasma concentration (Tmax) of CLB, N-CLB, CBD and CBD major metabolites. [ Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose. ]
    The Tmax of CLB, N-CLB, CBD and CBD major metabolites are presented.
  • Area under the curve (AUC) from zero to the final time of positive detection (0-t) of CLB, N-CLB, CBD and CBD major metabolites. [ Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose. ]
    The AUC(0-t) of CLB, N-CLB, CBD and CBD major metabolites are presented.
  • AUC from zero to infinity with extrapolation of the terminal phase (0-∞) of CLB, N-CLB, CBD and CBD major metabolites. [ Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose. ]
    The AUC(0-∞) of CLB, N-CLB, CBD and CBD major metabolites are presented.
  • Terminal half-life (t½) of CLB, N-CLB, CBD and CBD major metabolites. [ Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose. ]
    The t½ of CLB, N-CLB, CBD and CBD major metabolites are presented.
Change History Complete list of historical versions of study NCT02565108 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 26, 2018)
Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: Postdose on Day 2 up to Safety follow-up (Day 71) ]
A TEAE was defined as an adverse event with an onset date on or after the first dose of IMP. If an adverse event (AE) had a partial onset date and it was unclear from the partial date (or the stop date) whether the AE started prior to or following the first dose of IMP then the AE was considered a TEAE. The number of participants who experienced 1 or more severe TEAEs after screening up to Day 71. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
Original Secondary Outcome Measures  ICMJE
 (submitted: September 29, 2015)
  • Number of participants who experienced an adverse event. [ Time Frame: Up to 12 weeks. ]
    The number of participants who experienced an adverse event during the trial is presented.
  • Number of participants with a clinically significant change in serum biochemistry. [ Time Frame: Up to 8 weeks. ]
    The number of participants with a clinically significant change in serum biochemistry is presented.
  • Number of participants with a clinically significant change in hematology. [ Time Frame: Up to 8 weeks. ]
    The number of participants with a clinically significant change in hematology is presented.
  • Number of participants with a clinically significant change in urinalysis. [ Time Frame: Up to 8 weeks. ]
    The number of participants with a clinically significant change in urinalysis is presented.
  • Number of participants with a treatment-emergent suicidality flag. [ Time Frame: Up to 8 weeks. ]
    Suicidality was assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). The number of participants with a treatment-emergent flag is presented.
  • Number of participants with a clinically significant change in vital signs. [ Time Frame: Up to 8 weeks. ]
    The number of participants with a clinically significant change in vital signs (systolic blood pressure, diastolic blood pressure, pulse rate) is presented.
  • Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG). [ Time Frame: Up to 8 weeks. ]
    The number of participants with a clinically significant change in ECG is presented.
  • Number of participants with a clinically significant change in physical examination. [ Time Frame: Up to 8 weeks. ]
    The number of participants with a clinically significant change in physical examination is presented.
  • Seizure frequency by subtype [ Time Frame: Up to 5 weeks. ]
    The frequency of each subtype of seizure at baseline and end of treatment is presented.
  • Cmax of delta-9-tetrahydrocannabinol (THC) and its major metabolites. [ Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose. ]
    The Cmax of THC and its major metabolites are presented.
  • Tmax of THC and its major metabolites. [ Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose. ]
    The Tmax of THC and its major metabolites are presented.
  • AUC(0-t) of THC and its major metabolites. [ Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose. ]
    The AUC(0-t) of THC and its major metabolites are presented.
  • AUC(0-∞) of THC and its major metabolites. [ Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose. ]
    The AUC(0-∞) of THC and its major metabolites are presented.
  • t½ of THC and its major metabolites. [ Time Frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours post-dose. ]
    The t½ of THC and its major metabolites are presented.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
Official Title  ICMJE A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (GWP42003-P)
Brief Summary This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record. Participants were randomized in a 4:1 ratio to receive GWP42003-P or matching placebo.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Epilepsy
Intervention  ICMJE
  • Drug: GWP42003-P 20 mg/kg/Day Dose
    GWP42003-P was an oral solution containing 25 mg/mL cannabidiol (CBD) or 100 mg/mL CBD dissolved in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
    Other Names:
    • CBD
    • Cannabidiol
    • Epidiolex
  • Drug: Placebo
    Placebo oral solution contained the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
  • Drug: Clobazam
    Participants were already on a stable dose of CLB at Baseline and continued to take a stable dose of CLB for the duration of the blinded phase of the study. CLB was administered either once or twice daily in line with the physician's preferred dosing regimen for the CLB for each participant.
    Other Name: CLB
Study Arms  ICMJE
  • Experimental: GWP42003-P 20 mg/kg/Day Dose

    Participants received GWP42003-P 20 milligrams [mg]/kilogram [kg]/day orally, twice daily immediately after their clobazam (CLB) dose. Participants titrated GWP42003-P to 20 mg/kg/day over 10 days and remained at this dose for the 21-day treatment period. Participants who then did not enter the open-label extension (OLE) or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their GWP42003-P treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.

    All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an Investigational Medicinal Product (IMP), for the duration of this study.

    Interventions:
    • Drug: GWP42003-P 20 mg/kg/Day Dose
    • Drug: Clobazam
  • Placebo Comparator: Placebo

    Participants received placebo (0 mg/milliliter [mL] GWP42003-P) orally, twice daily immediately after the participant's CLB dose. Participants titrated the placebo dose over 10 days, followed by a 21-day treatment period. Participants who then did not enter the OLE or withdrew early had a 10-day taper (10% per day) period. Participants who transferred to the OLE (still blinded at that stage) tapered off their placebo treatment by reducing their maintenance dose by 10% per day and concomitantly titrating GWP42003-P for the OLE.

    All participants (in the GWP42003-P and Placebo treatment groups) were on a stable dose of CLB at Baseline, administered either once or twice daily as per the physician's preferred CLB dosing regimen for each participant, and continued taking CLB, as an IMP, for the duration of this study.

    Interventions:
    • Drug: Placebo
    • Drug: Clobazam
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 29, 2015)
20
Original Estimated Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE July 21, 2016
Actual Primary Completion Date July 21, 2016   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • Participant must have had epilepsy, as determined by the investigator, and must have been taking CLB.
  • Participant must have had a documented magnetic resonance imaging/computerized tomography of the brain ruling out a progressive neurologic condition.
  • Participant must have experienced at least 1 seizure of any type (that is, convulsive: tonic-clonic, tonic, clonic, atonic; focal: focal seizures with retained consciousness and a motor component, focal seizures with impaired consciousness, focal seizures evolving to bilateral secondary generalization) within the 2 months prior to randomization.
  • Participant must have been taking CLB and no more than 2 other antiepileptic drugs (AEDs) during the course of the trial.
  • AED(s), including CLB, must have been stable for 4 weeks prior to screening and regimen must have remained stable throughout the duration of the blinded phase of the trail.
  • Intervention with vagus nerve stimulation and/or ketogenic diet must be stable for 4 weeks prior to Baseline and participant/caregiver must have been willing to maintain a stable regimen throughout the blinded phase of the study.

Key Exclusion Criteria:

  • Participant had clinically significant unstable medical conditions other than epilepsy.
  • Participants were on CLB at doses above 20 mg per day.
  • Participants taking CLB intermittently as rescue medication.
  • Participant had a history of symptoms related to a drop in blood pressure due to postural changes (for example, dizziness, light-headedness, blurred vision, palpitations, weakness, syncope).
  • Participant had any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale in the last month or at screening.
  • Participant had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to screening or enrollment, other than epilepsy.
  • Participant had consumed alcohol during the 7 days prior to enrollment and was unwilling to abstain during the blinded phase of the trail.
  • Participant was currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the 3 months prior to trial entry.
  • Participant had any known or suspected history of any drug abuse or addiction.
  • Participant was unwilling to abstain from recreational or medicinal cannabis, or synthetic cannabinoid based medications (including Sativex) for the duration for the study.
  • Participant consumed grapefruit or grapefruit juice 7 days prior to enrollment and was unwilling to abstain from drinking grapefruit juice within 7 days of pharmacokinetic visits.
  • Participant had any known or suspected hypersensitivity to cannabinoids or any of the excipients of the IMP, for example, sesame oil.
  • Participant received an IMP within the 12 weeks prior to the screening visit.
  • Participant had significantly impaired hepatic function at the screening or randomization visit, defined as any of the following:

    • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 × upper limit of normal (ULN).
    • ALT or AST > 3 × ULN and total bilirubin > 2 × ULN or international normalized ratio > 1.5.
    • ALT or AST > 3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Spain,   United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02565108
Other Study ID Numbers  ICMJE GWEP1428 Blinded Phase
2014-002942-33 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party GW Research Ltd
Study Sponsor  ICMJE GW Research Ltd
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account GW Research Ltd
Verification Date July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP